| Drug Name: | Captopril (62571-86-2) |
|---|---|
| PubChem ID: | 44093 |
| SMILES: | C[C@H](CS)C(=O)N1CCC[C@H]1C(=O)O |
| InchiKey: | FAKRSMQSSFJEIM-RQJHMYQMSA-N |
| Therapeutic Category: | Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Cardiovascular Agents, Enzyme Inhibitors, Protease Inhibitors |
| Molecular Weight (dalton) | : | 217.29 |
| LogP | : | 0.6279 |
| Ring Count | : | 0 |
| Hydrogen Bond Acceptor Count | : | 3 |
| Hydrogen Bond Donor Count | : | 2 |
| Total Polar Surface Area | : | 57.61 |
This panel provides information on interacting drugs and their ADRs along with references
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|---|---|---|
| Bradycardia | Angiotensin-converting enzyme precursor (P12821) | Renoprotective effects@ blood-pressure reduction@ reduction in left ventricular mass@ endothelial function [ ADR Type 1 ] | Angiotensin-converting enzyme (ACE) inhibition in type 2, diabetic patients-- interaction with ACE insertion/deletion polymorphism Kidney |
| Bradycardia | Kallikrein (O43240) | Glandular kallikrein-kinin system in salivary glands regulates vasodilation, probably through the effect of kallikrein on plasma kininogen,which leads to decreased significantly blood pressure. [ ADR Type 1 ] | A Effects of furosemide and captopril on submaxillary gland blood flow and arterial pressure |
| Bradycardia | Kinin (P01042) | Glandular kallikrein-kinin system in salivary glands regulates vasodilation, probably through the effect of kallikrein on plasma kininogen,which leads to decreased significantly blood pressure. [ ADR Type 1 ] | A Effects of furosemide and captopril on submaxillary gland blood flow and arterial pressure |
| Cough | B2 bradykinin receptor (P30411) | Bradykinin B(2) receptor gene polymorphism is associated with angiotensin-converting enzyme inhibitor-related cough [ ADR Type 2 ] | Bradykinin B(2) receptor gene polymorphism is associated with angiotensin-converting enzyme inhibitor-related cough |
| Ill Effects | Glucose transporter I (P11166) | Decreased expression of glucose transporter I may be associated with increased intracellular glucose and the resultant ill effects@captopril reversed the above high glucose-induced effects partly by enhancing glucose transporter I and II messenger RNA expressions. [ ADR Type 1 ] | Captopril reverses high glucose-induced effects on LLC-PK1 cells partly by enhancing facilitative glucose transporter messenger RNA expressions |
| Leukopenia | Beta-glucuronidase (P08236) | Granulocyte aggregation was shown by the turbidimetric method and cellular activation was confirmed by the release of the granule associated enzyme lysozyme and beta-glucuronidase@which possibly mediated mechanism of peripheral leukopenia [ ADR Type 1 ] | A Captopril-induced granulocyte aggregation A possible complement mediated mechanism of peripheral leukopenia |
| Peripheral Leukopenia | Lysozyme (P61626) | Granulocyte aggregation was shown by the turbidimetric method and cellular activation was confirmed by the release of the granule associated enzyme lysozyme and beta-glucuronidase@which possibly mediated mechanism of peripheral leukopenia [ ADR Type 1 ] | A Captopril-induced granulocyte aggregation A possible complement mediated mechanism of peripheral leukopenia |
| Proteinuria | Angiotensin-converting enzyme (Q9BYF1) | The unexpected incidence of reversible proteinuria induced by low doses of captopril@which angiotensin-converting enzyme (ACE) was reported to be increased simultaneously [ ADR Type 2 ] | A Captopril-induced proteinuria in hypertensive psoriatic patients |
| Resultant Ill Effects | Glucose transporter II (P11168) | Decreased expression of glucose transporter I may be associated with increased intracellular glucose and the resultant ill effects@captopril reversed the above high glucose-induced effects partly by enhancing glucose transporter I and II messenger RNA expressions [ ADR Type 1 ] | Captopril reverses high glucose-induced effects on LLC-PK1 cells partly by enhancing facilitative glucose transporter messenger RNA expressions |
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|---|---|
| Lo salt (a salt substitute containing 34.6 g potassium in every 100 g) | Hyperkalemia | Stockley’s drug interactions 8th edition; Stockley’s drug interactions 2008 pocket companion |
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category